Eiken Chemical Co., Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Eiken Chemical Co., Ltd.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
Where ¥100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥162Over the last 3 years, every ¥100 of reported profit came with ¥162 of operating cash.
Higher than 73% of Healthcare companies in Japan.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 59% of Healthcare companies in Japan.
Cash Locked Ratio
¥30For every ¥100 of sales, ¥30 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥32 tied up three years earlier.
More money tied up than 68% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 76% of Healthcare companies in Japan.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -3% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-3% / -5%In 3 years sales changed by -3% while total assets changed by -5%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
1.2×Debt due within a year is covered 1.2 times by its yearly operating cash.
Higher than 56% of Healthcare companies in Japan.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Higher than 52% of Healthcare companies in Japan.
Tangible Assets Ratio
99%Of every ¥100 the company owns, ¥99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 79% of Healthcare companies in Japan.
Tangible Net Worth Ratio
99%Of every ¥100 of net worth, ¥99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 80% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Eiken Chemical Co., Ltd. owes ¥0.30 for every ¥1 it owns. Net profit rose 66% in the year to Mar 2026, and shrank 14% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
22.5Investors pay ¥22.5 for every ¥1 of Eiken Chemical Co., Ltd.'s yearly profit, higher than 74% of Healthcare companies in Japan.
P/B ratio
1.81The share price is 1.81 times Eiken Chemical Co., Ltd.'s book value per share, higher than 58% of Healthcare companies in Japan.
Market cap
¥79.7 BThe total market value of all of Eiken Chemical Co., Ltd.'s shares at today's price (share price × number of shares), larger than 72% of Healthcare companies in Japan. PosiCap size class: Mini Cap.
Net worth (book value)
¥44.0 BWhat Eiken Chemical Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥1,336Net worth divided by the number of shares. The share price of ¥2,418 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
8.3%Eiken Chemical Co., Ltd. earned 8.3% on its shareholders' money over the last year, higher than 55% of Healthcare companies in Japan.
Owes vs Owns
0.30×Eiken Chemical Co., Ltd. owes ¥0.30 for every ¥1 it owns (low), lower than 61% of Healthcare companies in Japan.
Dividend yield
2.40%Eiken Chemical Co., Ltd. pays 2.40% of its share price as dividends a year, lower than 59% of dividend-paying Healthcare companies in Japan.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Profit growth
+66%Net profit rose 66% in the year to Mar 2026, and shrank 14% a year on average over 3 years.
Profit margin
8.8%Eiken Chemical Co., Ltd. keeps ¥9 of every ¥100 of revenue as net profit.
Cash quality
1.09×Cash from Eiken Chemical Co., Ltd.'s business was 1.09× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
100.7×Eiken Chemical Co., Ltd.'s operating profit covered its interest costs 100.7 times in the year to Mar 2026.
Cash vs debt
Net cashEiken Chemical Co., Ltd. held ¥4.0 B more cash than debt (net cash) at Mar 2026.
Questions
What is Eiken Chemical Co., Ltd.'s P/E ratio?
Investors pay ¥22.5 for every ¥1 of Eiken Chemical Co., Ltd.'s yearly profit, higher than 74% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Eiken Chemical Co., Ltd.: ¥79.7 B ÷ ¥44.0 B (31 Mar 2026) = 1.8.
What is Eiken Chemical Co., Ltd.'s return on equity?
Eiken Chemical Co., Ltd. earned 8.3% on its shareholders' money over the last year, higher than 55% of Healthcare companies in Japan.
How much does Eiken Chemical Co., Ltd. owe compared with what it owns?
Eiken Chemical Co., Ltd. owes ¥0.30 for every ¥1 it owns (low), lower than 61% of Healthcare companies in Japan.
Does Eiken Chemical Co., Ltd. pay a dividend?
Yes. Eiken Chemical Co., Ltd. pays 2.40% of its share price as dividends a year, lower than 59% of dividend-paying Healthcare companies in Japan.
Is Eiken Chemical Co., Ltd.'s revenue growing?
Revenue rose 3% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.